ClinicalTrials.gg
CompletedNCT05627557INShoreUpdated Oct 14, 2026Results posted

A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome

A Phase 3 interventional study of Obinutuzumab and MMF in Childhood Idiopathic Nephrotic Syndrome, sponsored by Hoffmann-La Roche. Completed at 35 sites in 9 countries. Open to participants aged 2 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Updated Oct 14, 2026Now CompletedResults posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
2 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies in Nephrotic Syndrome with a site in United States — 12 open to participants now, 13 under way, none of them phase 3. Nephrotic Syndrome · United States.

Enrollment
7th of 38
85 · median 26
Started
2023
with 2 others
Phase 3
4 of 51
none open now
Registered
48th of 51
by date

Among the 51 studies in Nephrotic Syndrome with a site in United States, this one is the 7th largest by enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2023, is one of 4 in phase 3, and was the 48th registered.

Nephrotic Syndrome

192 studies on the registry are indexed under Nephrotic Syndrome; 65 are open to participants now.

Browse Nephrotic Syndrome studies →

Open to participants now

12 of the 51 studies in Nephrotic Syndrome with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Nephrotic Syndrome studies recruiting now, 23 (46%) set no upper age limit and 22 (44%) stop at 75 or younger; 37 take children under 18; 4 take healthy volunteers.

This study: 2 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Nephrotic Syndrome with a site in United States, or all of them as a file.
02

Study summary

This open-label, randomized multicenter study is to assess the efficacy, safety, and pharmacokinetics (PK)/pharmacodynamics (PD) of obinutuzumab compared with mycophenolate mofetil (MMF) in children and young adults (aged >= 2-25 years) with frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS).

03

Conditions studied

  • Childhood Idiopathic Nephrotic Syndrome

Browse trials for

04

Who can participate

Ages eligible
2 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of frequently relapsing nephrotic syndrome (FRNS) or dependent nephrotic syndrome (SDNS) before the age of 18 years
  • Must be in complete remission defined by the absence of edema, UPCR \<= 0.2 g/g at screening and have three consecutive daily urine dipstick readings of trace or negative for protein within the week prior to randomization
  • Must have had at least one relapse in the 6 months prior to screening, after discontinuation of or while receiving oral corticosteroids and/or therapy to prevent relapses
  • Participants having received cyclophosphamide in the 6 months prior to randomization must have experienced at least 1 relapse subsequent to cyclophosphamide discontinuation
  • Estimated (eGFR) within normal range for age
  • For females of : participants who agree to remain abstinent (refrain from heterosexual intercourse) or use highly effective , during the treatment period and for 18 months after the final dose of obinutuzumab and for 6 weeks after the final dose of MMF
  • For males: participants who agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agree to refrain from donating sperm during the treatment period and for 90 days after the final dose of MMF

Exclusion criteria

Exclusion Criteria:

  • Secondary nephrotic syndrome
  • History of resistant nephrotic syndrome
  • History of genetic defects known to directly cause nephrotic syndrome
  • Treatment with other medications to prevent relapse, other than MMF or oral corticosteroids within 2 months prior to randomization
  • Pregnancy or breastfeeding or intending to become pregnant during the study or within 18 months after the final dose of obinutuzumab, or within 6 weeks after the final dose of MMF
  • Females of , including those who have had a tubal ligation, must have a negative serum pregnancy test result within 28 days prior to initiation of study treatment and a negative urine pregnancy test at Day 1, prior to randomization
  • History of organ or bone marrow transplant
  • Participation in another therapeutic trial within 30 days of enrollment or 5 half-lives of the drug
  • Intolerance or to study therapies
  • Participants demonstrating prior treatment failure to MMF as defined by two or more relapses in any 6-month period of time while receiving MMF for at least a 6-month duration
  • Participants in the judgment of the investigator likely to require systemic corticosteroids for reasons other than idiopathic nephrotic syndrome during the study
  • Active infection of any kind or any major episode of infection requiring hospitalization or treatment with IV anti-infective medications within 4 weeks prior to screening, or completion of oral anti-infectives within 2 weeks prior to randomization
  • History of or currently active primary or secondary immunodeficiency, including known history of (HIV) infection and other severe Immunodeficiency blood disorders
  • History of progressive multifocal leukoencephalopathy
  • History of or current cancer, including solid tumors, hematological , and carcinoma in situ within the past 5 years
  • Major surgery requiring hospitalization during the 4 weeks prior to screening or during screening
  • High risk for bleeding or any condition requiring plasmapheresis, intravenous immunoglobulin, or acute blood product transfusions
  • Evidence of any significant or uncontrolled concomitant disease that, in the investigator's judgment, would preclude participant's participation, including but not limited to nervous system, respiratory, cardiac, hepatic, endocrine, malignant, or gastrointestinal disorders
  • Currently active alcohol or drug abuse or history of alcohol or drug abuse
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    Obinutuzumab (Group A)

    Participants in Group A will receive obinutuzumab 1000 milligrams (mg) (or 20 mg/ kilogram \[kg\] for participants \<45 kg) administered by intravenous (IV) infusion on Days 1, 15, 168 (Week 24), and 182 (Week 26).

    Drug: Obinutuzumab · Drug: Prednisone · Drug: Methylprednisolone · Drug: Acetaminophen/ Paracetamol · Drug: Diphenhydramine Hydrochloride

  • Active comparator
    MMF (Group B)

    Participants in Group B will receive oral MMF 600 mg/m\^2 twice a day (BID) (target 1200 mg/m2/day in divided doses, maximum 2 g/day) to Week 52.

    Drug: MMF · Drug: Prednisone

Interventions

  • Obinutuzumab will be administered as per schedule specified in the respective arm.

  • DrugMMF

    MMF will be administered as per schedule specified in the respective arm.

  • Participants taking prednisone or equivalent at randomization will follow a guided tapering schedule to reach the goal of 0mg/day by Weeks 4-6 (and no later than Week 8 following randomization and continue without prednisone through Week 52.

    Also known as: Non-Investigational Medicinal Product

  • Methylprednisolone 80 mg (or 1.5 mg/kg if \</=45 kg) IV will be administered as premedication prior to infusions.

    Also known as: Non-Investigational Medicinal Product

  • DrugAcetaminophen/ Paracetamol

    Drug page: Acetaminophen

    Acetaminophen 15 mg/kg (maximum dose 1000 mg) will be administered PO as premedication prior to infusions.

    Also known as: Non-Investigational Medicinal Product

  • Diphenhydramine HCl 0.5-1 mg/kg (maximum dose 50 mg) will be administered PO or IV as premedication prior to infusions.

    Also known as: Non-Investigational Medicinal Product

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Complete Remission at Week 52

    Sustained complete remission was defined as first morning void urine protein-to-creatinine ratio (UPCR) ≤0.2 gram/gram (g/g) at Week 52 without the occurrence of relapse or any other intercurrent event (IE) (except treatment discontinuation for any reason \[TDAR\]). Participants with following IE were considered non-responders (except TDAR): After Week 8: 1) Relapse=Any of the following events: First-morning void UPCR ≥ 2 g/g; or dipstick urinalysis (UA) ≥3+ for 3 consecutive days (home-monitoring) \& most recent urine sample determined to have UPCR \>0.2 g/g as measured by the central laboratory ; or dipstick UA protein ≥ 3+ on any single day with edema \& urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory. 2) Any systemic corticosteroids usage for \>14 days in 30-day period. After randomization: 1) Initiation of any rescue therapy for idiopathic nephrotic syndrome (INS), as per investigator other than systemic corticosteroids. 2) Death.

    Time frame: At Week 52

Secondary outcomes

  1. Overall Relapse-free Survival (RFS)

    Overall RFS was defined as the time from randomization to first relapse or death. Relapse was defined as any of the following events: First-morning void UPCR ≥2 g/g; or dipstick UA ≥3+ for 3 consecutive days (home-monitoring) and the most recent urine sample determined to have UPCR \>0.2 g/g as measured by the central laboratory; or dipstick UA protein ≥3+ on any single day with edema and urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory. Participants who withdrew their consent were censored at the time of withdrawal. Participants who were lost to follow-up were censored at the last assessment during scheduled or unscheduled visits. Kaplan-Meier (KM) estimates were used to evaluate the median RFS.

    Time frame: Up to approximately 127.3 weeks

  2. Cumulative Corticosteroid Dose From Baseline to Week 52

    Cumulative corticosteroid dose was defined as the total dose received (mg/kg) of prednisone or equivalent, regardless of intercurrent events (relapse, rescue therapy, treatment discontinuation for any reason, and systemic corticosteroid usage for \> 14 days) in participants prior to experiencing death. Topical, intraarticular, or inhaled corticosteroids and IV methylprednisolone given as a pre-medication were not included in this analysis.

    Time frame: Baseline up to Week 52

  3. Relapses From Baseline to Week 52

    Relapses were evaluated using adjusted rate ratio from baseline to Week 52, regardless of IEs (relapse, TDAR \& systemic corticosteroid usage for \>14 days) in participants before receiving rescue therapy (RT)/experiencing death. Total number of relapses occurring during treatment period were evaluated by accounting for number of relapses experienced \& participant's follow-up time. Participant level relapse \& follow-up time data were aggregated, \& rate of relapses was compared between the two arms. Rate of relapse was analyzed using a negative binomial model with a log link \& log of each participant's follow up time as offset variable. Relapse=any of the following events: First-morning void UPCR ≥2 g/g; or dipstick UA ≥3+ for 3 consecutive days (home-monitoring) \& most recent urine sample determined to have UPCR \>0.2 g/g as measured by the central laboratory; or dipstick UA protein ≥ 3+ on any single day with edema \& urine sample determined to have UPCR \>0.2 g/g per central laboratory.

    Time frame: Baseline up to Week 52

  4. Percentage of Participants With Sustained Complete Remission at Week 76

    Sustained complete remission=first morning void UPCR ≤ 0.2 g/g at Week 76 without the occurrence of relapse or any other IE (except TDAR). Relapse=Any of the following events: First-morning void UPCR ≥ 2 g/g; or dipstick UA ≥3+ for 3 consecutive days (home-monitoring) \& the most recent urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory; or dipstick UA protein ≥ 3+ on any single day with edema \& urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory. Other IEs include: Any systemic corticosteroids usage for \>14 days in a 30 day period; Initiation of any rescue therapy for INS, other than systemic corticosteroids; Death or TDAR. Participants with FRNS/SDNS who were randomized into the study at least 24 weeks prior to the date of randomization for the final participant in the study were only analyzed in this endpoint. Percentages have been rounded off.

    Time frame: At Week 76

  5. Probability of RFS at Week 52

    Probability of RFS at Week 52 was defined as the percentage of participants remaining free of relapse or death at Week 52. Relapse was defined as any of the following events: First-morning void UPCR ≥2 g/g; or dipstick UA ≥3+ for 3 consecutive days (home-monitoring) and the most recent urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory; or dipstick UA protein ≥ 3+ on any single day with edema and urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory. Participants who withdrew their consent were censored at the time of withdrawal. Participants who were lost to follow-up were censored at the last assessment during scheduled or unscheduled visits. K-M method was used to estimate the RFS rate at Week 52. Percentages have been rounded off.

    Time frame: At Week 52

  6. Percentage of Participants Experiencing Edema Associated Relapse During the 52-week Treatment Period

    Edema-associated relapse definition is the same as the definition of relapse except that the edema-associated relapse definition additionally requires that participant edema is present and documented in the eCRF at the time of the relapse event. Relapse=any of the following events: First-morning void UPCR ≥ 2 g/g; or dipstick UA ≥3+ for 3 consecutive days (home-monitoring) \& the most recent urine sample determined to have UPCR \> 0.2 g/g, measured by the central laboratory; or dipstick UA protein ≥ 3+ on any single day with edema \& urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory. Percentages have been rounded off.

    Time frame: Baseline up to Week 52

  7. Mean Change From Baseline to Week 52 in Cure Glomerulonephropathy Network (CureGN) Edema Scale

    Mean Change in CureGN Edema scale was defined as the mean change in total edema severity from baseline to Week 52, regardless of relapse, systemic corticosteroids usage for \>14 days in a 30 day period, and treatment discontinuation due to any reason, in participants prior to receiving rescue therapy and assuming death has not occurred. The CureGN edema scale was used to assess the total edema severity. Participants were asked to report the location of edema they experienced over the last month from eight different body areas (whole body, face, hands, arms, abdomen, genitalia, legs, feet) and rate its severity on a 6-point Likert scale (0=absent to 5=worst imaginable), with total scores ranging from 0-40. Higher score indicated worst edema severity. Adjusted mean change in the CureGN edema scale scores from baseline to Week 52 has been reported.

    Time frame: Baseline up to Week 52

  8. Mean Change From Baseline to Week 52 in "General Fatigue" Domain of Pediatric Quality of Life Inventory (PedsQL)-Multidimensional Fatigue Scale (MFS) Total Score

    Mean Change in "General Fatigue" domain of PedsQL-MFS total score was defined as the mean change in total score of the "General Fatigue" domain from baseline to Week 52, regardless of relapse, systemic corticosteroids usage for \>14 days in a 30-day period, \& treatment discontinuation due to any reason, in participants prior to receiving rescue therapy \& assuming death did not occur. PedsQL MFS is an 18-item, self-reported measure designed to assess fatigue in participants with acute or chronic health conditions. This was a standard version with a 1-month recall period. The measure assessed three components of fatigue: General Fatigue (6 items), Sleep/Rest Fatigue (6 items), \& Cognitive Fatigue (6 items). General fatigue scores were based on a 5-point Likert response format, ranging from 0 (Never) to 4 (Almost Always) \& transformed to 0-100 total score. Higher score=less fatigue. Adjusted mean change in general fatigue domain scores from baseline to Week 52 has been reported.

    Time frame: Baseline up to Week 52

  9. Mean Change From Baseline to Week 52 in "Physical Functioning (PF)" Domain of PedsQL-4.0 Generic Core Scale

    Mean Change in PF domain of PedsQL = mean change in the PF score from baseline to Week 52, regardless of relapse, systemic corticosteroids usage for \>14 days in a 30-day period, \& treatment discontinuation due to any reason, in participants prior to receiving rescue therapy \& assuming death did not occur. The PedsQL 4.0 Generic Core Scale is a 23 item measure used to assess health-related quality of life, over a recall of either one month (standard version) or 7 days (acute version). The 4 core domains include PF (8 items), Emotional Functioning (5 items), Social Functioning (5 items), and School Functioning (5 items). Items are rated on a 5-point Likert scale ranging from 0 (never a problem) to 4 (almost always a problem). Once completed, items are reverse scored \& linearly transformed to 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0, with higher scores=better health-related quality of life. Adjusted mean change in PF domain scores from baseline to Week 52 has been reported.

    Time frame: Baseline up to Week 52

  10. 52-week Treatment Period: Number of Participants With Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. As pre-specified in the SAP, analysis excludes AEs reported following rescue treatment other than corticosteroids.

    Time frame: Up to Week 52

  11. Maximum Serum Concentration (Cmax) of Obinutuzumab

    Samples were collected pre- and post-infusion at Weeks 0, 2, 24, and 26 and single samples were collected at Weeks 4, 12, 32, and 52. Data reported is averaged over the weeks specified in the time frame.

    Time frame: Weeks 0-24 and Weeks 24-52

  12. Trough Concentration (Ctrough) of Obinutuzumab

    Samples were collected pre- and post-infusion at Weeks 0, 2, 24, and 26 and single samples were collected at Weeks 4, 12, 32, and 52. Data reported is averaged over the weeks specified in the time frame.

    Time frame: Weeks 0-24 and Weeks 24-52

  13. Area Under the Concentration-Time Curve of Obinutuzumab From Time 0 to 52 Weeks (AUC0-52)

    Samples were collected pre- and post-infusion at Weeks 0, 2, 24, and 26 and single samples were collected at Weeks 4, 12, 32, and 52. Data reported is averaged over the weeks specified in the time frame.

    Time frame: Weeks 0-52

  14. Percentage of Participants Achieving B-cell Depletion Analyzed Using High Sensitivity Flow Cytometry (HSFC) Over Time

    Time frame: Up to approximately 3 years

  15. Total Peripheral B-cell and B-cell Subsets Counts Over Time

    Time frame: Up to approximately 3 years

  16. Change From Baseline in Total Peripheral B-cell and B-cell Subsets Counts

    Time frame: Baseline up to approximately 3 years

07

Results

Posted Oct 14, 2026

Participant flow

A total of 85 participants with childhood onset of frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS) took part in the study at 32 investigative sites across 9 countries. The study is still ongoing.

Participant flow — Overall Study
MilestoneObinutuzumabMycophenolate Mofetil
Started4441
Completed13
Not completed4338
Withdrew: Physician decision01
Withdrew: Withdrawal by subject10
Withdrew: Ongoing in study4237

Outcome measures

PrimaryPercentage of Participants With Sustained Complete Remission at Week 52

Sustained complete remission was defined as first morning void urine protein-to-creatinine ratio (UPCR) ≤0.2 gram/gram (g/g) at Week 52 without the occurrence of relapse or any other intercurrent event (IE) (except treatment discontinuation for any reason \[TDAR\]). Participants with following IE were considered non-responders (except TDAR): After Week 8: 1) Relapse=Any of the following events: First-morning void UPCR ≥ 2 g/g; or dipstick urinalysis (UA) ≥3+ for 3 consecutive days (home-monitoring) \& most recent urine sample determined to have UPCR \>0.2 g/g as measured by the central laboratory ; or dipstick UA protein ≥ 3+ on any single day with edema \& urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory. 2) Any systemic corticosteroids usage for \>14 days in 30-day period. After randomization: 1) Initiation of any rescue therapy for idiopathic nephrotic syndrome (INS), as per investigator other than systemic corticosteroids. 2) Death.

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Complete Remission at Week 52
percentage of participantsObinutuzumabMycophenolate Mofetil
Percentage of Participants With Sustained Complete Remission at Week 5295.5 (89.30 to 100.00)73.2 (59.61 to 86.73)
Statistical analysis
  • Obinutuzumab vs Mycophenolate Mofetil · Cochran-Mantel-Haenszel · p = 0.0031 (Test 1 of 10 maintaining a fixed sequence testing for type I error control at two-sided alpha 0.05.) · Adjusted difference: 23.36 · 95% CI 6.85 to 38.90
SecondaryOverall Relapse-free Survival (RFS)

Overall RFS was defined as the time from randomization to first relapse or death. Relapse was defined as any of the following events: First-morning void UPCR ≥2 g/g; or dipstick UA ≥3+ for 3 consecutive days (home-monitoring) and the most recent urine sample determined to have UPCR \>0.2 g/g as measured by the central laboratory; or dipstick UA protein ≥3+ on any single day with edema and urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory. Participants who withdrew their consent were censored at the time of withdrawal. Participants who were lost to follow-up were censored at the last assessment during scheduled or unscheduled visits. Kaplan-Meier (KM) estimates were used to evaluate the median RFS.

Time frame:
Up to approximately 127.3 weeks
Reported as:
Median · weeks
Overall Relapse-free Survival (RFS)
weeksObinutuzumabMycophenolate Mofetil
Overall Relapse-free Survival (RFS)NA (NA to NA)93.4 (82.6 to NA)
Statistical analysis
  • Obinutuzumab vs Mycophenolate Mofetil · Log Rank · p = 0.0074 (Test 2 of 10 maintaining a fixed sequence testing for type I error control at two-sided alpha 0.05.) · Hazard ratio (hr): 0.25 · 95% CI 0.08 to 0.75Hazard ratios were estimated by Cox regression.
SecondaryCumulative Corticosteroid Dose From Baseline to Week 52

Cumulative corticosteroid dose was defined as the total dose received (mg/kg) of prednisone or equivalent, regardless of intercurrent events (relapse, rescue therapy, treatment discontinuation for any reason, and systemic corticosteroid usage for \> 14 days) in participants prior to experiencing death. Topical, intraarticular, or inhaled corticosteroids and IV methylprednisolone given as a pre-medication were not included in this analysis.

Time frame:
Baseline up to Week 52
Reported as:
Median · mg/kg
Cumulative Corticosteroid Dose From Baseline to Week 52
mg/kgObinutuzumabMycophenolate Mofetil
Cumulative Corticosteroid Dose From Baseline to Week 5210.07 (3.92 to 26.28)18.92 (6.73 to 55.10)
Statistical analysis
  • Obinutuzumab vs Mycophenolate Mofetil · Wilcoxon (Mann-Whitney) · p = 0.0391 (Test 3 of 10 maintaining a fixed sequence testing for type I error control at two-sided alpha 0.05.)
SecondaryRelapses From Baseline to Week 52

Relapses were evaluated using adjusted rate ratio from baseline to Week 52, regardless of IEs (relapse, TDAR \& systemic corticosteroid usage for \>14 days) in participants before receiving rescue therapy (RT)/experiencing death. Total number of relapses occurring during treatment period were evaluated by accounting for number of relapses experienced \& participant's follow-up time. Participant level relapse \& follow-up time data were aggregated, \& rate of relapses was compared between the two arms. Rate of relapse was analyzed using a negative binomial model with a log link \& log of each participant's follow up time as offset variable. Relapse=any of the following events: First-morning void UPCR ≥2 g/g; or dipstick UA ≥3+ for 3 consecutive days (home-monitoring) \& most recent urine sample determined to have UPCR \>0.2 g/g as measured by the central laboratory; or dipstick UA protein ≥ 3+ on any single day with edema \& urine sample determined to have UPCR \>0.2 g/g per central laboratory.

Time frame:
Baseline up to Week 52
Reported as:
Number · relapses per year
Relapses From Baseline to Week 52
relapses per yearObinutuzumabMycophenolate Mofetil
Relapses From Baseline to Week 520.090.63
Statistical analysis
  • Obinutuzumab vs Mycophenolate Mofetil · Log Link · p = 0.0015 (Test 4 of 10 maintaining a fixed sequence testing for type I error control at two-sided alpha 0.05.) · Adjusted rate ratio: 0.07 · 95% CI 0.02 to 0.37
SecondaryPercentage of Participants With Sustained Complete Remission at Week 76

Sustained complete remission=first morning void UPCR ≤ 0.2 g/g at Week 76 without the occurrence of relapse or any other IE (except TDAR). Relapse=Any of the following events: First-morning void UPCR ≥ 2 g/g; or dipstick UA ≥3+ for 3 consecutive days (home-monitoring) \& the most recent urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory; or dipstick UA protein ≥ 3+ on any single day with edema \& urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory. Other IEs include: Any systemic corticosteroids usage for \>14 days in a 30 day period; Initiation of any rescue therapy for INS, other than systemic corticosteroids; Death or TDAR. Participants with FRNS/SDNS who were randomized into the study at least 24 weeks prior to the date of randomization for the final participant in the study were only analyzed in this endpoint. Percentages have been rounded off.

Time frame:
At Week 76
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Complete Remission at Week 76
percentage of participantsObinutuzumabMycophenolate Mofetil
Percentage of Participants With Sustained Complete Remission at Week 7680.0 (62.47 to 97.53)61.9 (41.13 to 82.67)
Statistical analysis
  • Obinutuzumab vs Mycophenolate Mofetil · Cochran-Mantel-Haenszel · p = 0.1399 (Test 5 of 10 maintaining a fixed sequence testing for type I error control at two-sided alpha 0.05.) · Adjusted difference: 20.67 · 95% CI -7.87 to 45.15
SecondaryProbability of RFS at Week 52

Probability of RFS at Week 52 was defined as the percentage of participants remaining free of relapse or death at Week 52. Relapse was defined as any of the following events: First-morning void UPCR ≥2 g/g; or dipstick UA ≥3+ for 3 consecutive days (home-monitoring) and the most recent urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory; or dipstick UA protein ≥ 3+ on any single day with edema and urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory. Participants who withdrew their consent were censored at the time of withdrawal. Participants who were lost to follow-up were censored at the last assessment during scheduled or unscheduled visits. K-M method was used to estimate the RFS rate at Week 52. Percentages have been rounded off.

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Probability of RFS at Week 52
percentage of participantsObinutuzumabMycophenolate Mofetil
Probability of RFS at Week 5290.91 (77.57 to 96.49)70.73 (54.26 to 82.19)
Statistical analysis
  • Obinutuzumab vs Mycophenolate Mofetil · Z-test · p = 0.0153 (Ranked 6 of 10 in the fixed sequence for type I error control. P-value is nominal as the hierarchical testing stops at the first non-significant endpoint.) · Difference in event-free rate: 20.18 · 95% CI 3.86 to 36.49
SecondaryPercentage of Participants Experiencing Edema Associated Relapse During the 52-week Treatment Period

Edema-associated relapse definition is the same as the definition of relapse except that the edema-associated relapse definition additionally requires that participant edema is present and documented in the eCRF at the time of the relapse event. Relapse=any of the following events: First-morning void UPCR ≥ 2 g/g; or dipstick UA ≥3+ for 3 consecutive days (home-monitoring) \& the most recent urine sample determined to have UPCR \> 0.2 g/g, measured by the central laboratory; or dipstick UA protein ≥ 3+ on any single day with edema \& urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory. Percentages have been rounded off.

Time frame:
Baseline up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Edema Associated Relapse During the 52-week Treatment Period
percentage of participantsObinutuzumabMycophenolate Mofetil
Percentage of Participants Experiencing Edema Associated Relapse During the 52-week Treatment Period2.3 (0.00 to 6.68)14.6 (3.82 to 25.45)
Statistical analysis
  • Obinutuzumab vs Mycophenolate Mofetil · Cochran-Mantel-Haenszel · p = 0.0359 (Ranked 7 of 10 in the fixed sequence for type I error control. P-value is nominal as the hierarchical testing stops at the first non-significant endpoint.) · Adjusted difference: -12.73 · 95% CI -27.24 to 2.93
SecondaryMean Change From Baseline to Week 52 in Cure Glomerulonephropathy Network (CureGN) Edema Scale

Mean Change in CureGN Edema scale was defined as the mean change in total edema severity from baseline to Week 52, regardless of relapse, systemic corticosteroids usage for \>14 days in a 30 day period, and treatment discontinuation due to any reason, in participants prior to receiving rescue therapy and assuming death has not occurred. The CureGN edema scale was used to assess the total edema severity. Participants were asked to report the location of edema they experienced over the last month from eight different body areas (whole body, face, hands, arms, abdomen, genitalia, legs, feet) and rate its severity on a 6-point Likert scale (0=absent to 5=worst imaginable), with total scores ranging from 0-40. Higher score indicated worst edema severity. Adjusted mean change in the CureGN edema scale scores from baseline to Week 52 has been reported.

Time frame:
Baseline up to Week 52
Reported as:
Mean · score on a scale
Mean Change From Baseline to Week 52 in Cure Glomerulonephropathy Network (CureGN) Edema Scale
score on a scaleObinutuzumabMycophenolate Mofetil
Mean Change From Baseline to Week 52 in Cure Glomerulonephropathy Network (CureGN) Edema Scale-1.66 ± 0.320-2.23 ± 0.371
Statistical analysis
  • Obinutuzumab vs Mycophenolate Mofetil · ANCOVA · p = 0.2336 (Ranked 8 of 10 in the fixed sequence for type I error control.) · Difference in adjusted means: 0.57 · 95% CI -0.36 to 1.50
SecondaryMean Change From Baseline to Week 52 in "General Fatigue" Domain of Pediatric Quality of Life Inventory (PedsQL)-Multidimensional Fatigue Scale (MFS) Total Score

Mean Change in "General Fatigue" domain of PedsQL-MFS total score was defined as the mean change in total score of the "General Fatigue" domain from baseline to Week 52, regardless of relapse, systemic corticosteroids usage for \>14 days in a 30-day period, \& treatment discontinuation due to any reason, in participants prior to receiving rescue therapy \& assuming death did not occur. PedsQL MFS is an 18-item, self-reported measure designed to assess fatigue in participants with acute or chronic health conditions. This was a standard version with a 1-month recall period. The measure assessed three components of fatigue: General Fatigue (6 items), Sleep/Rest Fatigue (6 items), \& Cognitive Fatigue (6 items). General fatigue scores were based on a 5-point Likert response format, ranging from 0 (Never) to 4 (Almost Always) \& transformed to 0-100 total score. Higher score=less fatigue. Adjusted mean change in general fatigue domain scores from baseline to Week 52 has been reported.

Time frame:
Baseline up to Week 52
Reported as:
Mean · score on a scale
Mean Change From Baseline to Week 52 in "General Fatigue" Domain of Pediatric Quality of Life Inventory (PedsQL)-Multidimensional Fatigue Scale (MFS) Total Score
score on a scaleObinutuzumabMycophenolate Mofetil
Mean Change From Baseline to Week 52 in "General Fatigue" Domain of Pediatric Quality of Life Inventory (PedsQL)-Multidimensional Fatigue Scale (MFS) Total Score2.05 ± 2.3195.80 ± 2.653
Statistical analysis
  • Obinutuzumab vs Mycophenolate Mofetil · ANCOVA · p = 0.2742 (Ranked 9 of 10 in the fixed sequence for type I error control.) · Difference in adjusted means: -3.76 · 95% CI -10.49 to 2.98
SecondaryMean Change From Baseline to Week 52 in "Physical Functioning (PF)" Domain of PedsQL-4.0 Generic Core Scale

Mean Change in PF domain of PedsQL = mean change in the PF score from baseline to Week 52, regardless of relapse, systemic corticosteroids usage for \>14 days in a 30-day period, \& treatment discontinuation due to any reason, in participants prior to receiving rescue therapy \& assuming death did not occur. The PedsQL 4.0 Generic Core Scale is a 23 item measure used to assess health-related quality of life, over a recall of either one month (standard version) or 7 days (acute version). The 4 core domains include PF (8 items), Emotional Functioning (5 items), Social Functioning (5 items), and School Functioning (5 items). Items are rated on a 5-point Likert scale ranging from 0 (never a problem) to 4 (almost always a problem). Once completed, items are reverse scored \& linearly transformed to 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0, with higher scores=better health-related quality of life. Adjusted mean change in PF domain scores from baseline to Week 52 has been reported.

Time frame:
Baseline up to Week 52
Reported as:
Mean · score on a scale
Mean Change From Baseline to Week 52 in "Physical Functioning (PF)" Domain of PedsQL-4.0 Generic Core Scale
score on a scaleObinutuzumabMycophenolate Mofetil
Mean Change From Baseline to Week 52 in "Physical Functioning (PF)" Domain of PedsQL-4.0 Generic Core Scale5.80 ± 3.0626.15 ± 3.509
Statistical analysis
  • Obinutuzumab vs Mycophenolate Mofetil · ANCOVA · p = 0.9380 (Ranked 10 of 10 in the fixed sequence for type I error control.) · Difference in adjusted means: -0.35 · 95% CI -9.22 to 8.51
Secondary52-week Treatment Period: Number of Participants With Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. As pre-specified in the SAP, analysis excludes AEs reported following rescue treatment other than corticosteroids.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
52-week Treatment Period: Number of Participants With Adverse Events (AEs)
ParticipantsObinutuzumabMycophenolate Mofetil
52-week Treatment Period: Number of Participants With Adverse Events (AEs)4234
SecondaryMaximum Serum Concentration (Cmax) of Obinutuzumab

Samples were collected pre- and post-infusion at Weeks 0, 2, 24, and 26 and single samples were collected at Weeks 4, 12, 32, and 52. Data reported is averaged over the weeks specified in the time frame.

Time frame:
Weeks 0-24 and Weeks 24-52
Reported as:
Geometric mean · μg/mL
Maximum Serum Concentration (Cmax) of Obinutuzumab
μg/mLObinutuzumab
Weeks 0-24757 ± 24.2
Weeks 24-52668 ± 23.2
SecondaryTrough Concentration (Ctrough) of Obinutuzumab

Samples were collected pre- and post-infusion at Weeks 0, 2, 24, and 26 and single samples were collected at Weeks 4, 12, 32, and 52. Data reported is averaged over the weeks specified in the time frame.

Time frame:
Weeks 0-24 and Weeks 24-52
Reported as:
Geometric mean · μg/mL
Trough Concentration (Ctrough) of Obinutuzumab
μg/mLObinutuzumab
Weeks 0-247.96 ± 82.4
Weeks 24-527.44 ± 72.1
SecondaryArea Under the Concentration-Time Curve of Obinutuzumab From Time 0 to 52 Weeks (AUC0-52)

Samples were collected pre- and post-infusion at Weeks 0, 2, 24, and 26 and single samples were collected at Weeks 4, 12, 32, and 52. Data reported is averaged over the weeks specified in the time frame.

Time frame:
Weeks 0-52
Reported as:
Geometric mean · μg/mL*day
Area Under the Concentration-Time Curve of Obinutuzumab From Time 0 to 52 Weeks (AUC0-52)
μg/mL*dayObinutuzumab
Area Under the Concentration-Time Curve of Obinutuzumab From Time 0 to 52 Weeks (AUC0-52)68,000 ± 27.4
SecondaryPercentage of Participants Achieving B-cell Depletion Analyzed Using High Sensitivity Flow Cytometry (HSFC) Over Time
Time frame:
Up to approximately 3 years

Results for this outcome have not been posted.

SecondaryTotal Peripheral B-cell and B-cell Subsets Counts Over Time
Time frame:
Up to approximately 3 years

Results for this outcome have not been posted.

SecondaryChange From Baseline in Total Peripheral B-cell and B-cell Subsets Counts
Time frame:
Baseline up to approximately 3 years

Results for this outcome have not been posted.

Adverse events

Collected over AEs and SAEs: Up to Week 52 All-cause Mortality: Up to approximately 127.3 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Obinutuzumab0/44 (0%)7/44 (15.9%)42/44 (95.5%)
Mycophenolate Mofetil0/41 (0%)3/41 (7.3%)34/41 (82.9%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventObinutuzumabMycophenolate Mofetil
PneumoniaInfections and infestations2/440/41
Abdominal distensionGastrointestinal disorders0/441/41
Gastrointestinal infectionInfections and infestations0/441/41
Viral upper respiratory tract infectionInfections and infestations0/441/41
Neutrophil count decreasedInvestigations0/441/41
Nephrotic syndromeRenal and urinary disorders0/441/41
AgranulocytosisBlood and lymphatic system disorders1/440/41
LymphadenitisBlood and lymphatic system disorders1/440/41
NeutropeniaBlood and lymphatic system disorders1/440/41
Lower respiratory tract infection viralInfections and infestations1/440/41
Most frequent other events
Showing 10 of 34
Most frequent other events
EventObinutuzumabMycophenolate Mofetil
Upper respiratory tract infectionInfections and infestations13/4415/41
Infusion related reactionInjury, poisoning and procedural complications16/440/41
InfluenzaInfections and infestations9/444/41
PyrexiaGeneral disorders8/445/41
CoughRespiratory, thoracic and mediastinal disorders8/445/41
NasopharyngitisInfections and infestations4/447/41
Ear infectionInfections and infestations7/443/41
PneumoniaInfections and infestations7/442/41
BronchitisInfections and infestations6/442/41
SinusitisInfections and infestations6/443/41

Baseline characteristics

Efficacy-evaluable (EE) population included all randomized participants, whether or not the participant received the assigned treatment.

Age, Continuous
Age, Continuous(years)ObinutuzumabMycophenolate MofetilTotal
Mean10.4 ± 4.49.3 ± 4.49.9 ± 4.4
Sex: Female, Male
Sex: Female, Male(Participants)ObinutuzumabMycophenolate MofetilTotal
Female161430
Male282755
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ObinutuzumabMycophenolate MofetilTotal
Hispanic or Latino111021
Not Hispanic or Latino333164
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ObinutuzumabMycophenolate MofetilTotal
American Indian or Alaska Native000
Asian81523
Native Hawaiian or Other Pacific Islander000
Black or African American7512
White281947
More than one race112
Unknown or Not Reported011
08

Study locations

35 sites
  • Lucile Packard Children's Hospital - Stanford
    Palo Alto, California 94304-1601, United States
  • Nicklaus Children's Hospital
    Miami, Florida 33155-3009, United States
  • Nemours Children's Hospital
    Orlando, Florida 32827-7884, United States
  • University of South Florida
    Tampa, Florida 33606-3475, United States
  • Children's Healthcare of Atlanta Center for Advanced Pediatrics
    Atlanta, Georgia 30329-2309, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601-1915, United States
  • Levine Children's Hospital
    Charlotte, North Carolina 28203-5866, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22903, United States
  • UZ Gent
    Ghent, 9000, Belgium
  • Irmandade Da Santa Casa de Misericordia de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90020-090, Brazil
  • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo
    São Paulo, São Paulo 05403-000, Brazil
  • Peking University First Hospital
    Beijing, 102627, China
  • The First Affiliated Hospital of Sun Yat-sen University
    Guangzhou, 510080, China
  • The children's hospital , Zhejiang university school of medicine
    Hangzhou, 310003, China
  • Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, 430040, China
  • Xi'an Children's Hospital
    Xi'an, 710003, China
  • Henan Children's Hospital Zhengzhou Children's Hospital
    Zhengzhou, 450018, China
  • Chu Toulouse
    Toulouse, Haute-Garonne 31300, France
  • Hopital Femme Mere Enfants
    Bron, 69500, France
  • Hopital Henri Mondor
    Créteil, 94010, France
  • Hopital Robert Debre
    Paris, 75935, France
  • Istituto G Gaslini Ospedale Pediatrico IRCCS
    Genoa, Liguria 16147, Italy
  • Ospedale Infantile Regina Margherita - INCIPIT - PIN
    Turin, Piedmont 10126, Italy
  • Tokyo Metropolitan Children's Medical Center
    Fuchu-Shi, 183-0042, Japan
  • Kobe University Hospital
    Kobe, 650-0017, Japan
  • Shiga University Of Medical Science Hospital
    Ōtsu, 520-2192, Japan
  • Kitasato University Hospital
    Sagamihara-Shi, 252-0329, Japan
  • Dokkyo Medical University Hospital
    Shimotsuga-Gun, 321-0293, Japan
  • National Center for Child Health and Development
    Tokyo, 157-8535, Japan
  • Yokohama City University Medical Center
    Yokohama, 232-0024, Japan
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, Poland
  • Dzieciecy Szpital Kliniczny UCK WUM
    Warsaw, 02-091, Poland
  • Hospital Sant Joan de Deu - PIN
    Espluges de Llobregat, Barcelona 08950, Spain
  • Hospital Universitario Cruces
    Barakaldo, Vizcaya 48903, Spain
09

References and documents

Publications

  • Larkins NG, Hahn D, Liu ID, Willis NS, Craig JC, Hodson EM. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev. 2024 Nov 8;11(11):CD002290. doi: 10.1002/14651858.CD002290.pub6. PubMed 39513526 ↗
  • Dossier C, Bonneric S, Baudouin V, Kwon T, Prim B, Cambier A, Couderc A, Moreau C, Deschenes G, Hogan J. Obinutuzumab in Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome in Children. Clin J Am Soc Nephrol. 2023 Dec 1;18(12):1555-1562. doi: 10.2215/CJN.0000000000000288. Epub 2023 Sep 6. PubMed 37678236 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2023 to primary completion in Sep 2025, 29 months.

Results were first posted in Oct 2026, 1 year 1 month after primary completion.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Aug 2026, on Oct 14, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2022
First posted
Nov 25, 2022
StartActual
Mar 29, 2023
Primary completionActual
Sep 4, 2025
CompletionActual
Aug 27, 2026was Sep 2026
Results first posted
Oct 14, 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 14, 2026
Results
Results posted
posted Oct 14, 2026
Sites
1 site added, 5 sites removed
Show site
  • Istituto G Gaslini Ospedale Pediatrico IRCCS · Genoa, Italy
Show 5 removed
  • Memorial Healthcare System · Hollywood, United States
  • University of Utah - Primary Children's Hospital - PPDS · Salt Lake City, United States
  • Istituto G Gaslini Ospedale Pediatrico IRCCS - INCIPIT - PIN · Genoa, Italy
  • Hokkaido University Hospital · Hokkaido, Japan
  • Hyogo prefectural Kobe Children's Hospital · Hyogoken, Japan
Oct 14, 2026
Study completion
Sep 4, 2026→Aug 27, 2026 (actual)
Oct 14, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedPercentage of Participants withWith Sustained Complete Remission at 1 yearWeek 52Time frame: At Week 52
Oct 14, 2026
Documents
Secondary outcomes
10 edited, 1 time frame changed, 4 added, 1 removed, 2 description edited
What changed in the outcomes
  • EditedCumulative Corticosteroid Dose From Baseline to Week 52Time frame: At Week 52 → Baseline up to Week 52
  • EditedPercentage of Participants Experiencing Edema Associated Relapse During the 52-week Treatment PeriodTime frame: At Week 52 → Baseline up to Week 52
  • EditedPercentage of Participants withWith Sustained Complete Remission at Week 76Time frame: Week 52 to Week 76 → At Week 76
  • EditedMean Change From Baseline to Week 52 in "General Fatigue" Domain of Pediatric Quality of Life Inventory (PedsQL) -Multidimensional Fatigue Scale (MFS) Total ScoreTime frame: Baseline to Week 52 → Baseline up to Week 52
  • EditedMean Change From Baseline to Week 52 in "Physical Functioning (PF)" Domain of PedsQL Quality of Life Inventory-4.0 Generic Core ScaleTime frame: Baseline to Week 52 → Baseline up to Week 52
  • EditedMean Change From Baseline to Week 52 in Cure Glomerulonephropathy Network (CureGN) Edema ScaleTime frame: Baseline to Week 52 → Baseline up to Week 52
  • EditedPercentage52-week Treatment Period: Number of Participants withWith Adverse Events (AEs)Time frame: Baseline to Week 52 → Up to Week 52
  • EditedMaximum Serum ConcentrationsConcentration (Cmax) of ObinutuzumabTime frame: At Days 1, 15 28, 84, 168, 182, 224, 364, and at Early Study Discontinuation Visit (unscheduled visit at the time of discontinuation from study, any time between Day 1 and Day 364) → Weeks 0-24 and Weeks 24-52
  • EditedPercentage of Participants Achieving B Cell-cell Depletion Highly SensitiveAnalyzed Using High Sensitivity Flow Cytometry (HSFC) Over TimeTime frame: At Days 1, 15, 28, 84, 168, 224, 364, and at Early Study Discontinuation Visit (unscheduled visit at the time of discontinuation from study, any time between Day 1 and Day 364) → Up to approximately 3 years
  • EditedTotal Peripheral B Cell-cell and B Cell-cell Subsets (e.g., Memory B Cells) Counts and Change from BaselineOver TimeTime frame: At Days 1, 15, 28, 84, 168, 224, 364, and at Early Study Discontinuation Visit (unscheduled visit at the time of discontinuation from study, any time between Day 1 and Day 364) → Up to approximately 3 years
  • AddedRelapses From Baseline to Week 52Time frame: Baseline up to Week 52
  • AddedTrough Concentration (Ctrough) of ObinutuzumabTime frame: Weeks 0-24 and Weeks 24-52
  • AddedArea Under the Concentration-Time Curve of Obinutuzumab From Time 0 to 52 Weeks (AUC0-52)Time frame: Weeks 0-52
  • AddedChange From Baseline in Total Peripheral B-cell and B-cell Subsets CountsTime frame: Baseline up to approximately 3 years
  • RemovedNumber of RelapsesTime frame: At Week 52
  • Time frameOverall Relapse-free Survival (RFS)At Week 52 → Up to approximately 127.3 weeks
  • DescriptionOverall Relapse-free Survival (RFS): how it is measured was reworded
  • DescriptionProbability of RFS at Week 52: how it is measured was reworded
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Active, not recruiting→Completed
    Results posted
    1 site added, 5 sites removed
    Show site
    • Istituto G Gaslini Ospedale Pediatrico IRCCS · Genoa, Italy
    Show 5 removed
    • Memorial Healthcare System · Hollywood, United States
    • University of Utah - Primary Children's Hospital - PPDS · Salt Lake City, United States
    • Istituto G Gaslini Ospedale Pediatrico IRCCS - INCIPIT - PIN · Genoa, Italy
    • Hokkaido University Hospital · Hokkaido, Japan
    • Hyogo prefectural Kobe Children's Hospital · Hyogoken, Japan
    Study completion Sep 4, 2026→Aug 27, 2026 (now actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedPercentage of Participants withWith Sustained Complete Remission at 1 yearWeek 52Time frame: At Week 52
    Secondary outcomes 10 edited, 1 time frame changed, 4 added, 1 removed, 2 description edited
    What changed in the outcomes
    • EditedCumulative Corticosteroid Dose From Baseline to Week 52Time frame: At Week 52 → Baseline up to Week 52
    • EditedPercentage of Participants Experiencing Edema Associated Relapse During the 52-week Treatment PeriodTime frame: At Week 52 → Baseline up to Week 52
    • EditedPercentage of Participants withWith Sustained Complete Remission at Week 76Time frame: Week 52 to Week 76 → At Week 76
    • EditedMean Change From Baseline to Week 52 in "General Fatigue" Domain of Pediatric Quality of Life Inventory (PedsQL) -Multidimensional Fatigue Scale (MFS) Total ScoreTime frame: Baseline to Week 52 → Baseline up to Week 52
    • EditedMean Change From Baseline to Week 52 in "Physical Functioning (PF)" Domain of PedsQL Quality of Life Inventory-4.0 Generic Core ScaleTime frame: Baseline to Week 52 → Baseline up to Week 52
    • EditedMean Change From Baseline to Week 52 in Cure Glomerulonephropathy Network (CureGN) Edema ScaleTime frame: Baseline to Week 52 → Baseline up to Week 52
    • EditedPercentage52-week Treatment Period: Number of Participants withWith Adverse Events (AEs)Time frame: Baseline to Week 52 → Up to Week 52
    • EditedMaximum Serum ConcentrationsConcentration (Cmax) of ObinutuzumabTime frame: At Days 1, 15 28, 84, 168, 182, 224, 364, and at Early Study Discontinuation Visit (unscheduled visit at the time of discontinuation from study, any time between Day 1 and Day 364) → Weeks 0-24 and Weeks 24-52
    • EditedPercentage of Participants Achieving B Cell-cell Depletion Highly SensitiveAnalyzed Using High Sensitivity Flow Cytometry (HSFC) Over TimeTime frame: At Days 1, 15, 28, 84, 168, 224, 364, and at Early Study Discontinuation Visit (unscheduled visit at the time of discontinuation from study, any time between Day 1 and Day 364) → Up to approximately 3 years
    • EditedTotal Peripheral B Cell-cell and B Cell-cell Subsets (e.g., Memory B Cells) Counts and Change from BaselineOver TimeTime frame: At Days 1, 15, 28, 84, 168, 224, 364, and at Early Study Discontinuation Visit (unscheduled visit at the time of discontinuation from study, any time between Day 1 and Day 364) → Up to approximately 3 years
    • AddedRelapses From Baseline to Week 52Time frame: Baseline up to Week 52
    • AddedTrough Concentration (Ctrough) of ObinutuzumabTime frame: Weeks 0-24 and Weeks 24-52
    • AddedArea Under the Concentration-Time Curve of Obinutuzumab From Time 0 to 52 Weeks (AUC0-52)Time frame: Weeks 0-52
    • AddedChange From Baseline in Total Peripheral B-cell and B-cell Subsets CountsTime frame: Baseline up to approximately 3 years
    • RemovedNumber of RelapsesTime frame: At Week 52
    • Time frameOverall Relapse-free Survival (RFS)At Week 52 → Up to approximately 127.3 weeks
    • DescriptionOverall Relapse-free Survival (RFS): how it is measured was reworded
    • DescriptionProbability of RFS at Week 52: how it is measured was reworded
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05627557
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 25, 2022
Start date
Mar 29, 2023
Primary completion
Sep 4, 2025
Completion
Aug 27, 2026
Results posted
Oct 14, 2026
Last update
Oct 14, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obinutuzumab

Start the discussion